pharmacy

Nalidixic acid is a prescription drug given orally for the treatment of urinary tract infections caused by susceptible bacteria. Avoid use of this medicine if you have a history of kidney failure and or epilepsy.

Nalidixic acid is a prescription drug given orally for the treatment of urinary tract infections caused by susceptible bacteria. Avoid use of this medicine if you have a history of kidney failure and or epilepsy

Therapeutic indications For use as an additional therapy within a comprehensive treatment program including psychological guidance for detoxified patients who have been opioid-dependent & alcohol dependence to support abstinence. Posology and method of administration Use in adults Naltrexone treatment should be initiated and supervised by suitable qualified physicians. The initial dose of naltrexone hydrochloride should be 25 mg (half a tablet) for opioid-dependent patient followed by the usual dose of one tablet per day (= 50 mg naltrexone hydrochloride) A missed dose can be managed by providing 1 tablet per day each day till the next regular dosage-administration. Naltrexone administered to opioid-dependent persons can cause life-threatening withdrawal symptoms. Patients suspected of using or being addicted to opioids must undergo a naloxone provocation test , unless it can be verified that the patient has not taken any opioids for 7-10 days (urine test) prior to the initiation of treatment with naltrexone. As Naltrexone is an adjunctive therapy and the full recovery process in opioid-dependent patients is individually variable, no standard duration of treatment can be stated; an initial period of three months should be considered. However, prolonged administration may be necessary. The recommended dose for alcohol dependence to support abstinence is 50 mg per day (1 tablet). A dose of over 150 mg on any single day is not recommended, since this can lead to a higher incidence of side effects. As naltrexone hydrochloride is an adjunctive therapy and the full recovery process from alcohol dependence is individually variable, no standard duration of treatment can be stated; an initial period of three months should be considered. However, prolonged administration may be necessary The dosage-regimen can be modified in order to improve compliance to a three-times-a-week dosing schedule as follows: administration of 2 tablets (=100 mg naltrexone hydrochloride) on Monday and on Wednesday and 3 tablets (=150 mg naltrexone hydrochloride) on Friday. Lactose Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Interaction with other medicinal products and other forms of interaction Concomitant administration of naltrexone with an opioid-containing medication should be avoided. Fertility, pregnancy and lactation Pregancy There are no clinical data on naltrexone hydrochloride use in pregnancy. Data from animal studies have shown reproductive toxicity. The data are insufficient to establish clinical relevance. The potential risk for humans is unknown. Naltrexone should only be given to pregnant women when, in the judgement of the attending physician the potential benefits outweigh and the possible risk. The use of naltrexone in pregnant alcoholic patients receiving long-term treatment with opiates or substitution treatment with opiates, or in pregnant patients who are opioid-dependent, creates a risk of acute withdrawal syndrome which could have serious consequences for the mother and the foetus. Naltrexone administration must be suspended if opiate analgesics are prescribed. Lactation: There are no clinical data on naltrexone HCl use in lactation. It is unknown whether naltrexone or 6-beta-naltrexol is excreted in human breast milk. During treatment breast feeding is not recommended. Adverse effects Very common (At least 1 in every 10 people) Nervousness Anxiety Insomnia Headache Sleep disorders Restlessness Abdominal pain Abdominal cramps Nausea or inclination to vomit Vomitting Arthralgia- Joint stiffness. Myalgia-Muscle pain Feebleness Asthenia-The body loses strength Common(?1/100 to <1/10) Decreased appetite Affective disorders Despondency- A period of low spirit Irritability Mood swings Dizziness Shivering Vertigo Lycrimation increase Tachycardia Palpitations Electrocardiogram change Chest pain Diarrhoea Constipation Skin rash Urine retention Delayed ejaculation Lack of appetite Thirst Increased energy Chills Uncommon (?1/1,000 to < 1/100) Oral herpes Tinea pedis- Athletes foot Lymphadenopathy Hallucinations Confusion state Depression Paranoia Disorientation Nightmares Agitation Libido disorder Abnormal dreams Rare (? 1/10,000 to < 1/1,000) Idiopathic thrombocytopenia Suicidal Ideation Attempted suicide Speech disorder Very rare (< 1/10,000) Euphoria Exanthema-Diffuse skin rash Rhabdomyolysis- The breakdown of muscle tissue that leads to the release of muscle fiber contents into the blood.

Multiple Dose Glass Fliptop Vial, 1 x 25 x 10mL Naloxone Hydrochloride Injection, USP Brand Name Equivalent: Narcan NDC 00409-1219-01 / 00409121901 Concentration: 0.4 mg/mL Content: 0.4 mg/10mL Non-DEHP Preservative-Free Non-Returnable